Glypressin

Glypressin is an injectable medication containing the active ingredient terlipressin acetate. It is supplied as a sterile solution for intravenous use and is marketed in the European Union. As a vasopressin analog, Glypressin acts as a vasoconstrictor. The product is prescription‑only and is employed under medical supervision for the management of bleeding esophageal varices and selected cases of hepatorenal syndrome in adult patients under specialist care.

Glypressin is prescribed for specific conditions where reduction of portal pressure or improvement of renal perfusion is required.

- Control of acute bleeding from esophageal varices in patients with portal hypertension. - Management of hepatorenal syndrome associated with advanced liver disease. - Adjunct therapy in selected cases of refractory hypotension due to septic shock, when vasopressin response is inadequate. - Temporary support of systemic vascular resistance during liver transplantation procedures. - Prevention of re‑bleeding after initial endoscopic control of variceal hemorrhage, when standard pharmacologic agents are insufficient. - Use in clinical trials evaluating renal function improvement in cirrhotic patients with acute kidney injury.

The safety profile of Glypressin reflects its vasoconstrictive activity; side effects are reported across a range of frequencies, from mild and transient reactions that often resolve spontaneously to potentially life‑threatening events that require prompt medical management.

Common: - Headache, often mild, transient, and not requiring specific treatment. - Nausea or vomiting, typically occurring shortly after infusion and usually manageable with anti‑emetics. - Flushing or warmth at the injection site, usually resolving without intervention within minutes.

Serious: - Severe hypertension or hypertensive crisis, which may necessitate rapid‑acting antihypertensive therapy and close monitoring. - Cardiac arrhythmias, including tachycardia or bradycardia, that may require electrocardiographic monitoring and possible pharmacologic intervention. - Peripheral ischemia with risk of tissue necrosis, especially in distal extremities, demanding immediate cessation of the drug and vascular assessment.

When prescribing Glypressin, clinicians should consider several precautionary measures to minimize risk and ensure appropriate patient selection.

- Assess baseline blood pressure and cardiovascular status before initiating therapy. - Monitor hemodynamic parameters, including blood pressure and heart rate, throughout the infusion. - Use caution in patients with pre‑existing coronary artery disease or peripheral vascular disease. - Evaluate renal function and fluid balance, especially in those with advanced liver disease. - Avoid rapid bolus administration; prefer controlled infusion rates as recommended. - Discontinue promptly if signs of severe hypertension, ischemia, or allergic reaction develop.

Glypressin may interact with other agents that affect vascular tone, cardiac function, or renal perfusion; awareness of these interactions helps guide safe co‑administration.

Avoid: - Concomitant use of other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) that could exacerbate hypertension. - Direct-acting cardiac glycosides in patients with unstable cardiac conditions. - Uncontrolled severe hypertension, where additional vasoconstriction may be hazardous.

Use with caution: - Diuretics or other agents influencing intravascular volume, requiring close monitoring of fluid status. - Beta‑blockers, as combined effects on heart rate and blood pressure may be unpredictable. - Anticoagulants, because changes in hemodynamics can affect bleeding risk. - Renin‑angiotensin system inhibitors, as combined vasodilatory and vasoconstrictive effects may lead to unstable blood pressure.